McKesson Corporation (MCK)
|Net Income (ttm)||3.14B|
|Ex-Dividend Date||Nov 30, 2022|
|Day's Range||355.73 - 364.54|
|52-Week Range||260.73 - 401.78|
|Price Target||430.88 (+18.5%)|
|Earnings Date||Feb 1, 2023|
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]
Financial PerformanceFinancial Statements
According to 20 analysts, the average rating for MCK stock is "Buy." The 12-month stock price forecast is $430.88, which is an increase of 18.50% from the latest price.
The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in...
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.
McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.
McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 third-quarter financial results. Results can be accessed on McKesson's Investor Relations website at inv...
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services...
There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on...
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson Receives Approval of Its Near-term Climate Change Targets by the Globally Recognized Science Based Targets initiative
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets th...
Investors target stocks that have been on a bullish run lately. Stocks like HRI, DCP, MRC and MCK that are seeing price strength have a high chance of carrying the momentum forward.
Here is how McKesson (MCK) and Doctor Reddy's (RDY) have performed compared to their sector so far this year.
Some of the best performers have been owned by Buffett for decades, like Coca-Cola, while others are new additions to the portfolio, like T-Mobile.
In the latest trading session, McKesson (MCK) closed at $375.12, marking no change from the previous day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third-quarter fiscal 2023 financial results after market close on Wednesday, February 1, 2023. The company will host...
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.